SKF India – Results Update

The net sales have risen by 14% to Rs387.0 crore. The company benefited from the buoyancy in the industrial division where it was able to report a healthy top line growth against a slowdown in the automotive segment.

The operating profit margin has improved by 620 basis points to 17.6%, leading to a brilliant 76.5% growth in the operating profit to Rs68.3 crore. We believe that a better product mix in favour of industrial bearings and greater operational efficiencies triggered the margin growth.

The net profit has grown by 92.5% to Rs43.1 crore against our expectations of Rs37.2 crore. In view of the company’s brilliant performance, we are upgrading our CY2007 estimate by 9.2% to Rs30.1 and CY2008 estimate by 7.2% to Rs35.8.

Biocon Approval + Divestment of Enzymes business

Biocon has received the necessary approvals from DCGI (drug controller general of India) to market ABRAXANE (nanoparticles based, albumin bound paclitaxel) in India. ABRAXANE has been approved for use in the treatment of breast cancer and will facilitate affordable access of high-quality supportive care therapy to cancer patients in India.

The global revenue for ABRAXANE reached $175 million in the first phase of its launch. Globally ABRAXANE has shown a positive trend in market penetration for metastatic breast cancer. According to IMS data, for the period between February and September 2006 versus the same period the previous year, there was a 64% unit growth in ABRAXANE versus a 11% increase in the overall taxane market.

Biocon completed the formalities with respect to the divestment of its Enzymes business vertical to Novozymes South Asia, a wholly owned subsidiary of Novozymes A/s of Denmark for $115 million on 01 October 2007. The post tax proceeds of this divestment will enable Biocon to strategically focus on its core bio-pharmaceuticals business as well as consider key acquisition opportunities to move up the value chain. This divestment will contribute a one time exceptional net gain this fiscal.

Supreme Infra Lists with 70% premium

Supreme Infrastructure India, an infrastructure development company primarily engaged in civil construction activities, has listed at Rs 187.50, a premium of 73.61% premium over its offer price of Rs 108 on the NSE.

You can now check the allotment status of Maytas Infra IPO.

You can also read about the Reliance Power IPO ir-regularities by promoter family, Anil Ambani.

Kotak Upgrades CONCOR + Gateway Distriparks

Kotak has upgraded the stocks of Container Corporation of India Ltd [CONCOR] and Gateway Distriparks Ltd after the Q2 results.

CONCOR:
You can see the Q2 results flash in our earnings news section. Here is the rationale behind the upgrade. Accommodating for lower average realizations, lower operating margins, higher other income and lower then expected average tax rates, Kotak revises earnings estimates and expect the company to report EPS of Rs.125.0 in FY08E and Rs.145.1 in FY09E as against earlier estimates of Rs.126.7 and Rs.149.3, respectively.

At Rs.1885, the stock trades at 3.0x book value, 13.0x earnings and 11.4x cash earnings based on FY09E. Concor has a tremendous advantage in terms of its scale of operations consisting of volume of traffic, network of terminals across the country, strong base of low cost assets like hi-speed wagons and containers, which would ensure its No.1 position in India in the visible future for transportation of containers through rail. Kotak reiterates BUY on Concor with a revised price target of Rs.2875.

Gateway Distriparks Ltd: GDL
Q2FY08 results of Gateway Distriparks were above expectation on the revenues side. However, the margins have disappointed us. On the profitability side, the results were below expectations.

On a consolidated basis net sales for Q2FY08 were at Rs.640.3 mn, up 67.8% on YoY basis and up 32.5% on sequential basis. EBIDTA for Q2FY08 was at Rs.255.5 mn, up 16.6% YoY and up 15.9% on sequential basis. Consolidated PAT for Q2FY08 was at Rs.188.8 mn, down 10.4% YoY and up 1.6% on sequential basis thereby translating into quarterly EPS of Rs.1.6 and quarterly CEPS of Rs.2.2.

Gateway Rail Freight Ltd, subsidiary of GDL, has acquired its first own container train and subsequently it deployed two of its own rakes on the domestic route. The cold chain business of the company through Snowman Frozen Foods has done well as the revenues grew by 10.1% on sequential basis to Rs.71.4 mn.

Expect GDL to report EPS of Rs.7.2 in FY08E and Rs.9.5 in FY09E, as against earlier estimates of Rs.8.2 and Rs.10.7, respectively. Revised Target price is Rs 170.

Citi Upgrades Jubilant Organosys

Jubilant’s 2QFY08 results were very strong, with a robust trend in revenues as well as profitability. The high margin PLSPS business (especially CRAMS) was the key growth driver and now contributes c60% of revenues.

2QFY08 was stronger than expected, with sales growth of 33% YoY (16% organic) & 169 bps expansion in EBIDTA margins leading to a
49% increase in recurring PAT. Reported PAT was buoyed by forex translation gains (Rs289m). CRAMS was the key growth driver while the legacy industrial and performance products business benefited from lower molasses prices.

Citi raised FY08E, FY09E and FY10E net profit estimates by 41%, 5% and 3% respectively. The company is expected to report an EPS of Rs 17.37, 22.11 and 27.00 for FY08, 09 and 10 respectively. Citi also raised the stock target price by 8% to Rs 415/share.

1 46 47 48 49 50 173